Is BioXcel Therapeutics, Inc. overvalued or undervalued?

As of 12 August 2025, the valuation grade for BioXcel Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is overvalued given its current metrics, particularly with a Price to Book Value of -0.12, an EV to EBIT of -1.74, and an EV to EBITDA of -1.75, all of which suggest severe financial distress and negative returns on capital employed.
In comparison to its peers, C4 Therapeutics, Inc. has a P/E of -1.7285 and an EV to EBITDA of 0.1350, while Champions Oncology, Inc. stands out with a very attractive P/E of 19.9287 and an EV to EBITDA of 13.1831, highlighting how BioXcel's metrics fall short against more stable companies in the sector. Additionally, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -49.69% compared to the index's gain of 12.22%, reinforcing the notion that BioXcel is currently overvalued.